Jing Wang

Also affiliated with Novartis (Switzerland), Fujian Medical University, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Beijing Technology and Business University, Shanxi University, Capital Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Xinjiang Production and Construction Corps, Academy of Military Medical Sciences, Soochow University, Beijing VDJBio (China), Henan University Huaihe Hospital and Huaihe Clinical Institute, National Cancer Center, First Affiliated Hospital of Guangzhou Medical University, Novartis (United States), National Clinical Research, Songjiang District Central Hospital, The Affiliated Yongchuan Hospital of Chongqing Medical University, Hanzhong People's Hospital, Cancer Hospital of Chinese Academy of Medical Sciences, Guizhou Provincial People's Hospital, Beijing Shijitan Hospital, Tongji Hospital, Qilu Hospital of Shandong University, Fu Wai Hospital, First Affiliated Hospital of Jinan University, Huazhong University of Science and Technology, Southern Medical University, Zhejiang University, Chongqing Medical University, Guangzhou Medical University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations”.